Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
Anthony J Garcia-PratsSusan E PurchaseMuhammad OsmanHeather R DraperH Simon SchaafLubbe WiesnerPaolo DentiAnneke C HesselingPublished in: Antimicrobial agents and chemotherapy (2019)
This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (n = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult tablets had 41% lower bioavailability than the novel dispersible tablets, resulting in much higher exposures with the dispersible tablets with the same dose.
Keyphrases
- multidrug resistant
- drug resistant
- young adults
- gram negative
- acinetobacter baumannii
- mycobacterium tuberculosis
- klebsiella pneumoniae
- electronic health record
- big data
- randomized controlled trial
- machine learning
- childhood cancer
- emergency department
- escherichia coli
- hiv aids
- study protocol
- hepatitis c virus
- pulmonary tuberculosis
- human immunodeficiency virus
- meta analyses